Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been nearly a year since my last Sarepta Therapeutics (NASDAQ: SRPT ) article , when the ticker was trading near $160 per share. At that time, Sarepta was riding high on the FDA’s landmark expanded approval ofHe is the leader of the investing grou ...